flatexDEGIRO AG

  • WKN: FTG111
  • ISIN: DE000FTG1111
  • Land: Deutschland

Nachricht vom 06.10.2021 | 12:28

DGAP-DD: flatexDEGIRO AG english


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
06.10.2021 / 12:27
The issuer is solely responsible for the content of this announcement.

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Name and legal form: Carpio GmbH

2. Reason for the notification

a) Position / status
Person closely associated with:
Title:
First name: Frank
Last name(s): Niehage
Position: CEO

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
flatexDEGIRO AG

b) LEI
529900IRBZTADXJB6757 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE000FTG1111

b) Nature of the transaction
Acquisition

c) Price(s) and volume(s)
Price(s) Volume(s)
17.65 EUR 10060.50 EUR
17.65 EUR 6177.50 EUR
17.65 EUR 10060.50 EUR
17.65 EUR 176.50 EUR
17.43 EUR 4357.50 EUR
17.38 EUR 10080.40 EUR
17.38 EUR 5561.60 EUR
17.38 EUR 10080.40 EUR
17.39 EUR 10086.20 EUR
17.39 EUR 3304.10 EUR

d) Aggregated information
Price Aggregated volume
17.4863 EUR 69945.2000 EUR

e) Date of the transaction
2021-10-06; UTC+2

f) Place of the transaction
Name: Tradegate Exchange
MIC: TGAT



06.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021